Open AccessAssessment of potential public health impact of a quadrivalent inactivated influenza vaccine in T hailand
Author(s) -
Kittikraisak Wanitchaya,
Chittaganpitch Malinee,
Gregory Christopher J.,
Laosiritaworn Yongjua,
Thantithaveewat Thanawadee,
Dawood Fatimah S.,
Lindblade Kim A.
Publication year - 2016
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12361
Subject(s) - medicine , influenza vaccine , population , influenza like illness , vaccination , public health , human mortality from h5n1 , virology , live attenuated influenza vaccine , seasonal influenza , incidence (geometry) , influenza season , emergency medicine , environmental health , virus , covid-19 , disease , nursing , physics , infectious disease (medical specialty) , optics
Background Each year, an influenza B strain representing only one influenza B lineage is included in the trivalent inactivated influenza vaccine ( IIV 3); a mismatch between the selected lineage and circulating viruses can result in suboptimal vaccine effectiveness. We modeled the added potential public health impact of a quadrivalent inactivated influenza vaccine ( IIV 4) that includes strains from both influenza B lineages compared to IIV 3 on influenza‐associated morbidity and mortality in Thailand. Methods Using data on the incidence of influenza‐associated hospitalizations and deaths, vaccine effectiveness, and vaccine coverage from the 2007–2012 influenza seasons in Thailand, we estimated rates of influenza‐associated outcomes that might be averted using IIV 4 instead of IIV 3. We then applied these rates to national population estimates to calculate averted illnesses, hospitalizations, and deaths for each season. We assumed that the influenza B lineage included in IIV 3 would provide a relative vaccine effectiveness of 75% against the other B lineage. Results Compared to use of IIV 3, use of IIV 4 might have led to an additional reduction ranging from 0·4 to 14·3 influenza‐associated illnesses per 100 000 population/year, <0·1 to 0·5 hospitalizations per 100 000/year, and <0·1 to 0·4 deaths per 1000/year. Based on extrapolation to national population estimates, replacement of IIV 3 with IIV 4 might have averted an additional 267–9784 influenza‐associated illnesses, 9–320 hospitalizations, and 0–3 deaths. Conclusion Compared to use of IIV 3, IIV 4 has the potential to further reduce the burden of influenza‐associated morbidity and mortality in Thailand.